These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 17447410)

  • 1. Levodopa in the treatment of Parkinson's disease.
    Fahn S
    J Neural Transm Suppl; 2006; (71):1-15. PubMed ID: 17447410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new look at levodopa based on the ELLDOPA study.
    Fahn S
    J Neural Transm Suppl; 2006; (70):419-26. PubMed ID: 17017562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
    Poewe WH; Deuschl G; Gordin A; Kultalahti ER; Leinonen M;
    Acta Neurol Scand; 2002 Apr; 105(4):245-55. PubMed ID: 11939936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation.
    Chan PL; Nutt JG; Holford NH
    Pharm Res; 2007 Apr; 24(4):791-802. PubMed ID: 17308968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bromocriptine versus levodopa in early Parkinson's disease.
    Ramaker C; van Hilten JJ
    Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotection for Parkinson's disease.
    Koller WC
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S155-9. PubMed ID: 9749588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study.
    Snow BJ; Macdonald L; Mcauley D; Wallis W
    Clin Neuropharmacol; 2000; 23(2):82-5. PubMed ID: 10803797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease.
    Gottwald MD
    Pharmacotherapy; 1999 Nov; 19(11 Pt 2):162S-8S. PubMed ID: 10555944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Early treatment of Parkinson's disease with levodopa].
    Odekerken VJ; Post B; Verschuur CV; de Bie RM
    Ned Tijdschr Geneeskd; 2009; 153():A286. PubMed ID: 19785822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unmet medical needs in Parkinson's disease.
    Koller WC; Tse W
    Neurology; 2004 Jan; 62(1 Suppl 1):S1-8. PubMed ID: 14718675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
    Del Dotto P; Pavese N; Gambaccini G; Bernardini S; Metman LV; Chase TN; Bonuccelli U
    Mov Disord; 2001 May; 16(3):515-20. PubMed ID: 11391748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacological therapy of complicated Parkinson's disease].
    Jiménez-Jiménez FJ; Molina JA
    Rev Neurol; 1997 Aug; 25 Suppl 2():S170-9. PubMed ID: 9280685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
    Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
    Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
    Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
    Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa strengths and weaknesses.
    Jankovic J
    Neurology; 2002 Feb; 58(4 Suppl 1):S19-32. PubMed ID: 11909982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.